Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic search or meta-analysis
PubMed 24177063 · doi:10.1097/GRF.0b013e3182a98295
What was done
The author reviewed clinical considerations regarding bisphosphonate safety, focusing on the risk of atypical femoral fractures during long-term therapy and the rationale and timing for intermittent treatment discontinuation ("drug holidays").
What was found
The abstract provides no quantitative data or statistical estimates. It reports that the fracture-reduction benefits of bisphosphonates substantially outweigh the risk of atypical femoral fractures over the first 10 years of use. Because residual fracture protection declines slowly after cessation while atypical fracture risk decreases rapidly, the author suggests a 1- to 2-year drug holiday after 3 to 5 years of therapy, except for patients at very high risk of fracture.
Why it matters
It provides clinical guidance on balancing long-term fracture prevention against rare adverse events like atypical femoral fractures through structured treatment pauses.
Limits
The abstract describes a narrative review presenting expert recommendations rather than primary empirical data or a systematic review. No specific numerical risk-benefit estimates, sample sizes, or study selection criteria are reported.
Cited by
- context Bisphosphonates are clinically indicated for only 3 to 5 years of use.